73
Views
7
CrossRef citations to date
0
Altmetric
Original Research

The inspiratory capacity/total lung capacity ratio as a predictor of survival in an emphysematous phenotype of chronic obstructive pulmonary disease

, , , &
Pages 1305-1312 | Published online: 13 Jul 2015

References

  • Centers for Disease Control and Prevention (CDC)Deaths from chronic obstructive pulmonary disease United States, 2000–2005MMWR Morb Mortal Wkly Rep200857451229123219008792
  • XuJQKochanekKDMurphySLTejeda-VeraBDeaths: Final Data for 2007 National Vital Statistics Reports5819Hyattsville, MDNational Health Center for Health Statistics2010 Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_19.pdfAccessed January 20, 2015
  • Centers for Disease Control and Prevention (CDC)Cigarette smoking among adults – United States, 2006MMWR Morb Mortal Wkly Rep200756441157116117989644
  • AlbuquerqueALNeryLEVillaçaDSInspiratory fraction and exercise impairment in COPD patients with GOLD stages II–IIIEur Respir J200628593994416870665
  • BourdinABurgelPRChanezPGarciaGPerezTRocheNRecent advances in COPD: pathophysiology, respiratory physiology and clinical aspects, including comorbiditiesEur Respir J200918114198212
  • CalverlyPMAndersonJACelliBTORCH investigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med200735677578917314337
  • CasanovaCCoteCMarinJMDistance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPDChest2008134474675218625667
  • CasanovaCCoteCde TorresJPInspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2005171659159715591470
  • Soler-CataluñaJJMartínez-GarcíaMARomán SánchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
  • CelliBRVestboJJenkinsCRInvestigators of the TORCH StudySex differences in mortality and clinical expressions of patients with chronic obstructive pulmonary disease. The TORCH experienceAm J Respir Crit Care Med2011183331732220813884
  • CelliBRDecramerMKestenSLiuDMehraSTashkinDPUPLIFT Study InvestigatorsMortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20091801094895519729663
  • CelliBartolome RPredictors of mortality in COPDRespir Med201010477377920417082
  • CoteCGPinto-PlataVKasprzykKDordellyLJCelliBRThe 6-min walk distance, peak oxygen uptake, and mortality in COPDChest200713261778178517925409
  • FanVSCurtisJRTuSPMcDonellMBFihnSDAmbulatory Care Quality Improvement Project InvestigatorsUsing quality of life to predict hospitalization and mortality in patients with obstructive lung diseasesChest2002122242943612171813
  • MartinezFJFosterGCurtisJLNETT Research GroupPredictors of mortality in patients with emphysema and severe airflow obstructionAm J Respir Crit Care Med2006173121326133416543549
  • NishimuraKIzumiTTsukinoMOgaTDyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPDChest200212151434144012006425
  • OgaTNishimuraKTsukinaMHealth status measured with the CRQ does not predict mortality in COPDEur Respir J20022051147115112449167
  • OgaTNishimuraKTsukinoMSatoSHajiroTAnalysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health statusAm J Respir Crit Care Med2003167454454912446268
  • Pinto-PlatoVMCoteCCabralHTaylorJCelliBRThe 6-min walk distance: change over time and value as a predictor of survival in severe COPDEur Respir J2004231283314738227
  • SabinoPGSilvaBMBrunettoAFNutritional status is related to fat-free mass, exercise capacity and inspiratory strength in severe chronic obstructive pulmonary disease patientsClinics (Sao Paulo)201065659960520613936
  • RingbaekTSeersholmNViskumKStandardised mortality rates in females and males with COPD and asthmaEur Respir J200525589189515863648
  • SinDDAnthonisenNRSorianoJBAgustiAGMortality in COPD: role of comorbiditiesEur Respir J20062861245125717138679
  • SinDDWuLAndersonJAInhaled corticosteroids and mortality in chronic obstructive pulmonary diseaseThorax2005601299299716227327
  • TantucciCDonatiPNicosiaFInspiratory capacity predicts mortality in patients with chronic obstructive pulmonary diseaseRespir Med2008102461361918083020
  • de TorresJPCoteCGLópezMVSex differences in mortality in patients with COPDEur Respir J200933352853519047315
  • DecramerMJanssensWMiravitllesMChronic obstructive pulmonary diseaseLancet201237998231341135122314182
  • FletcherCPetoRThe natural history of chronic airflow obstructionBMJ19771607716451648871704
  • JenkinsCRJonesPWCalverleyPMEfficacy of salmeterol/fluticasone by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyRespir Res2009105919566934
  • CelliBRThomasNEAndersonJAEffects of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH studyAm J Respir Crit Care Med2008178433233818511702
  • DecramerMCelliBRKestenSLystigTMehraSTashkinDPUPLIFT investigatorsEffect of triotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trialLancet200937496961171117819716598
  • GanWQManSFSenthilselvanASinDDAssociation between chronic obstructive pulmonary disease and systemic inflammation: a systemic review and a meta-anaylsisThorax200459757458015223864
  • MiravitllesMAnzuetoAInsights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studiesInt J Chron Obstruct Pulmon Dis2009418520119516917
  • SorianoJBSinDDZhangXA pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placeboChest2007131368268917356080
  • CelliBRCoteCGMarinJMThe body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary diseaseN Engl J Med2004350101005101214999112
  • GlaabTVogelmeierCBuhlROutcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitationsRespir Res2010117920565728
  • FreitasCGPereiraCAViegasCAInspiratory capacity, exercise limitations, markers of severity, and prognostic factors in chronic obstructive pulmonary diseaseJ Bras Pneumol200733438939617982530
  • LandboCPrescottELangePVestboJAlmdalTPPrognostic value of nutritional status in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med199916061856186110588597
  • MarinJMCarrizoSJGasconMSanchezAGallegoBCelliBRInspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200116361395139911371407
  • PuhanMAGarcia-AymerichJFreyMExpansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO indexLancet2009374969170471119716962
  • VassauxCTorre-BouscouletLZeineldineSEffects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPDEur Respir J20083251275128218550609
  • DiazOVillafrancaCGhezzoHRole of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitations at restEur Respir J200016212561276
  • O’DonnellDERevilleSMWebbKADynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001164577077711549531
  • CrapoROMorrisAHClaytonPDNixonCRLung volumes in healthy nonsmoking adultsBull Eur Physiopathol Respir19821834194257074238
  • MillerAThortonJCWarshawRAndersonHTeirsteinASSelikoffIJSingle breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking historyAm Rev Respir Dis198312732702776830050
  • PauwelsRABuistASCalverleyPMJenkinsCRHurdSSGOLD Scientific CommitteeGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summaryAm J Respir Crit Care Med200116351256127611316667
  • Rationale and Design of The National Emphysema Treatment Trial: a prospective randomized trial of lung volume reduction surgery. The National Emphysema Treatment Trial Research GroupChest199911661750176110593802
  • AnthonisenNRSkeansMAWiseRAManfredJKannerREConnettJELung Health Study Research GroupThe effects of smoking cessation intervention on 14.5-year mortalityAnn Intern Med2005142423323915710956
  • FergusonGTWhy does the lung hyperinflate?Proc Am Thorac Soc20063217617916565428
  • National Heart, Lung, and Blood InstituteGlobal Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: NHLBI/NIH Workshop ReportBethesda, MDNational Heart, Lung, and Blood Institute2001 Available from: http://www.goldcopd.org/uploads/users/files/GOLDWkshp2001pdfAccessed January 20, 2015